Sandu Pharmaceuticals Limited (BOM:524703)

Market Cap	369.24M -20.4%
Revenue (ttm)	696.24M +4.2%
Net Income	17.71M +10.1%
EPS	2.02 +21.5%
Shares Out	9.66M
PE Ratio	18.92
Forward PE	n/a
Dividend	1.00 (2.62%)
Ex-Dividend Date	Sep 4, 2026

Volume	9,507
Open	38.99
Previous Close	38.12
Day's Range	37.00 - 38.99
52-Week Range	30.00 - 50.50
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Sandu Pharmaceuticals

Sandu Pharmaceuticals Limited manufactures and sells ayurvedic medicines under the SANDU brand in India and internationally. It offers immunity monsoon kit, sandu balm, sandu aptilift, sandu mahasudarshan kadha, sandu abhayarishta, sandu pathyadi kadha, sandu makarprash, sandu gulkand pravalyukta, sandu acivin herbal antacid, sandu ashwagandharishta, sandu amritarishta, sandu hemocleen excellent blood purifier, and sandu vanari granules. The company also provides mahasudarshan kadha, amritarishta, tab. samshamani vati, pathajeevani, vasa cough ...

• Industry: Pharmaceutical Preparations
• Founded: 1899
• Employees: 258
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524703

Financial Performance

In fiscal year 2026, Sandu Pharmaceuticals's revenue was 699.35 million, an increase of 4.08% compared to the previous year's 671.92 million. Earnings were 17.66 million, an increase of 14.03%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 7, 2026

Data Sources Report a data error